-
Something wrong with this record ?
Association of Genetic Variants of Dopamine and Serotonin In Schizophrenia
R. Zakharyan, H. Ghazaryan, L. Kocourkova, A. Chavushyan, A. Mkrtchyan, V. Zizkova, A. Arakelyan, M. Petrek,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Antipsychotic Agents therapeutic use MeSH
- Cytochrome P-450 CYP2D6 genetics MeSH
- Dopamine genetics metabolism MeSH
- Adult MeSH
- Gene Frequency MeSH
- Genetic Predisposition to Disease MeSH
- Genetic Association Studies MeSH
- Genotype MeSH
- Polymorphism, Single Nucleotide * MeSH
- Catechol O-Methyltransferase genetics MeSH
- Middle Aged MeSH
- Humans MeSH
- Metabolic Networks and Pathways genetics MeSH
- Young Adult MeSH
- Receptors, Dopamine genetics MeSH
- Receptors, Serotonin genetics MeSH
- Schizophrenia drug therapy genetics MeSH
- Aged MeSH
- Serotonin genetics metabolism MeSH
- Case-Control Studies MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: Several studies indicated that antipsychotic treatment response and side effect manifestation can be different due to inter-individual variability in genetic variations. AIM OF THE STUDY: Here we perform a case-control study to explore a potential association between schizophrenia and variants within the antipsychotic drug molecular targets (DRD1, DRD2, DRD3, HTR2A, HTR6) and metabolizing enzymes (CYP2D6, COMT) genes in Armenian population including also analysis of their possible relationship with disease clinical symptoms. METHODS: A total of 18 SNPs was studied in patients with schizophrenia (n = 78) and healthy control subjects (n = 77) using MassARRAY genotyping. RESULTS: We found that two studied genetic variants, namely DRD2 rs4436578*C and HTR2A rs6314*A are underrepresented in the group of patients compared to healthy subjects. After the correction for multiple testing, the rs4436578*C variant remained significant while the rs6314*A reported borderline significance. No significant differences in minor allele frequencies for other studied variants were identified. Also, a relationship between the genotypes and age of onset as well as disease duration has been detected. CONCLUSIONS: The DRD2 rs4436578*C genetic variant might have protective role against schizophrenia, at least in Armenians.
Andranik Chavushyan Institute of Molecular Biology NAS RA Yerevan Armenia
Department of Psychiatry National Institute of Health MH RA Yerevan Armenia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025285
- 003
- CZ-PrNML
- 005
- 20201222155138.0
- 007
- ta
- 008
- 201125s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.arcmed.2019.12.011 $2 doi
- 035 __
- $a (PubMed)32086104
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Zakharyan, Roksana $u Institute of Molecular Biology NAS RA, Yerevan, Armenia; Russian-Armenian, University, Yerevan, Armenia. Electronic address: r_zakharyan@mb.sci.am.
- 245 10
- $a Association of Genetic Variants of Dopamine and Serotonin In Schizophrenia / $c R. Zakharyan, H. Ghazaryan, L. Kocourkova, A. Chavushyan, A. Mkrtchyan, V. Zizkova, A. Arakelyan, M. Petrek,
- 520 9_
- $a BACKGROUND: Several studies indicated that antipsychotic treatment response and side effect manifestation can be different due to inter-individual variability in genetic variations. AIM OF THE STUDY: Here we perform a case-control study to explore a potential association between schizophrenia and variants within the antipsychotic drug molecular targets (DRD1, DRD2, DRD3, HTR2A, HTR6) and metabolizing enzymes (CYP2D6, COMT) genes in Armenian population including also analysis of their possible relationship with disease clinical symptoms. METHODS: A total of 18 SNPs was studied in patients with schizophrenia (n = 78) and healthy control subjects (n = 77) using MassARRAY genotyping. RESULTS: We found that two studied genetic variants, namely DRD2 rs4436578*C and HTR2A rs6314*A are underrepresented in the group of patients compared to healthy subjects. After the correction for multiple testing, the rs4436578*C variant remained significant while the rs6314*A reported borderline significance. No significant differences in minor allele frequencies for other studied variants were identified. Also, a relationship between the genotypes and age of onset as well as disease duration has been detected. CONCLUSIONS: The DRD2 rs4436578*C genetic variant might have protective role against schizophrenia, at least in Armenians.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antipsychotika $x terapeutické užití $7 D014150
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a katechol-O-methyltransferasa $x genetika $7 D002394
- 650 _2
- $a cytochrom P-450 CYP2D6 $x genetika $7 D019389
- 650 _2
- $a dopamin $x genetika $x metabolismus $7 D004298
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a frekvence genu $7 D005787
- 650 _2
- $a genetické asociační studie $7 D056726
- 650 _2
- $a genetická predispozice k nemoci $7 D020022
- 650 _2
- $a genotyp $7 D005838
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a metabolické sítě a dráhy $x genetika $7 D053858
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a jednonukleotidový polymorfismus $7 D020641
- 650 _2
- $a receptory dopaminové $x genetika $7 D011954
- 650 _2
- $a receptory serotoninové $x genetika $7 D011985
- 650 _2
- $a schizofrenie $x farmakoterapie $x genetika $7 D012559
- 650 _2
- $a serotonin $x genetika $x metabolismus $7 D012701
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ghazaryan, Hovsep $u Andranik Chavushyan, Institute of Molecular Biology NAS RA, Yerevan, Armenia.
- 700 1_
- $a Kocourkova, Lenka $u Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Chavushyan, Andranik $u Andranik Chavushyan, Institute of Molecular Biology NAS RA, Yerevan, Armenia.
- 700 1_
- $a Mkrtchyan, Artur $u Department of Psychiatry, National Institute of Health, MH RA, Yerevan, Armenia.
- 700 1_
- $a Zizkova, Veronika $u Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Arakelyan, Arsen $u Institute of Molecular Biology NAS RA, Yerevan, Armenia; Russian-Armenian, University, Yerevan, Armenia.
- 700 1_
- $a Petrek, Martin $u Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
- 773 0_
- $w MED00000548 $t Archives of medical research $x 1873-5487 $g Roč. 51, č. 1 (2020), s. 13-20
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32086104 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222155133 $b ABA008
- 999 __
- $a ok $b bmc $g 1599430 $s 1115971
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 51 $c 1 $d 13-20 $e 20200218 $i 1873-5487 $m Archives of medical research $n Arch Med Res $x MED00000548
- LZP __
- $a Pubmed-20201125
